Next 10 |
VANCOUVER, Wash. and NEW YORK, July 03, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced that on July 1, 2024, the company granted a non-statutory stock option to purchase an aggregate of 613,000 shares of its common stoc...
2024-07-03 10:51:31 ET More on Absci Absci: 'AI' Tag Keeping Company Afloat While Searching For Right Formula Absci Corporation (ABSI) Q1 2024 Earnings Call Transcript Seeking Alpha’s Quant Rating on Absci Historical earnings data for Absci Fin...
VANCOUVER, Wash. and NEW YORK, June 12, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the upcoming Morgan Stanley 3 rd Annual Life Sciences AI Summit on June 26-27 in New York, ...
VANCOUVER, Wash. and NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the upcoming Goldman Sachs 45 th Annual Global Healthcare Conference in Miami, FL. Absci...
2024-05-24 16:58:54 ET Gainers: Photronics ( PLAB ) +6% . Replimune Group ( REPL ) +4% . Caribou Biosciences ( CRBU ) +3% . Symbotic ( SYM ) +3% . Arhaus ( ARHS ) +3% . Losers: OneMedNet ( ONMD ) -...
2024-05-23 16:47:49 ET Gainers: Ross Stores ( ROST ) +6% . Frontier Group Holdings ( ULCC ) +4% . Caribou Biosciences ( CRBU ) +4% . Absci Corporation ( ABSI ) +3% . Protara Therapeutics ( TARA ) +3% . Losers: Domo ( DO...
2024-05-16 18:36:07 ET Summary Absci Corporation, an AI-driven drug discovery company, has seen its share price plummet after its IPO in July 2021. Nearly all AI-driven drug discovery companies have struggled with overall share price performance since IPO. Absci's stock has be...
2024-05-14 13:30:24 ET Absci Corporation. (ABSI) Q1 2024 Earnings Conference Call May 14, 2024 8:30 AM ET Company Participants Alex Khan – Vice President, Finance and Investor Relations Sean McClain – Founder and Chief Executive Officer Zach Jonasso...
2024-05-14 07:36:10 ET More on Absci Absci: Differentiated Antibody Discovery Play Absci prices $75M equity offering at $4.50 per share Seeking Alpha’s Quant Rating on Absci Historical earnings data for Absci Financial information for Absci ...
Initiated IND-enabling studies for ABS-101 in February Continuing to advance ABS-201 and ABS-301 through preclinical studies VANCOUVER, Wash. and NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today re...
News, Short Squeeze, Breakout and More Instantly...
VANCOUVER, Wash. and NEW YORK, July 03, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced that on July 1, 2024, the company granted a non-statutory stock option to purchase an aggregate of 613,000 shares of its common stoc...
VANCOUVER, Wash. and NEW YORK, June 12, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the upcoming Morgan Stanley 3 rd Annual Life Sciences AI Summit on June 26-27 in New York, ...
VANCOUVER, Wash. and NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the upcoming Goldman Sachs 45 th Annual Global Healthcare Conference in Miami, FL. Absci...